rasagiline

CLINICAL USE

Treatment of Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

1 mg daily

PHARMACOKINETICS

Molecular weight :267.3 (as mesilate)

%Protein binding :60–70

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :243 litres

half-life – normal/ESRD (hrs) :0.6–2/unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Likely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Analgesics: avoid concomitant use with dextromethorphan; avoid concomitant use with pethidine (risk of serious adverse reactions) – allow at least 14 days before starting pethidine

Antidepressants: avoid concomitant use with other MAOIs (can lead to hypertensive crisis) – allow at least 14 days before starting a MAOI; avoid concomitant use with fluoxetine and fluvoxamine; allow 5 weeks between stopping fluoxetine and starting rasagiline; allow 14 days between stopping rasagiline and starting fluoxetine or fluvoxamine; increased CNS toxicity with SSRIs and tricyclics

Sympathomimetics: concomitant use is not recommended

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Rasagiline is an irreversible selective inhibitor of monoamine oxidase type B.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home